|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 01, 2016 ) The opioids also affect the discharge of digestive enzymes that can sometime cause partial gastro paresis. Some of the most familiar symptoms of opioid-induced constipation includes, hard and dry stools, swelling, painful defecation, distention and protruded abdomen, tiredness, and loss of hunger. Some of the most common opioid-induced constipation therapy is the use of targeted therapies, OTC and off-label drugs and changing lifestyle.
To know more visit: https://www.psmarketresearch.com/market-analysis/opioid-induced-constipation-market
Based on the drug action mechanism the global opioid-induced constipation market can be segmented as: peripherally acting mu-opioid receptor antagonist, locally acting chloride channel activator, and others. Based on the administration route of drugs the global opioid-induced constipation market can be segmented into two broad categories: oral and parental.
On the basis of different form of drug the global opioid-induced constipation market can be bifurcated into two broad categories: solid and liquid. Some of the dominant market drivers for opioid-induced constipation includes, rising number of OIC patients, and widespread use of opioids treatment in chronic non-cancer pain. The current opioid-induced constipation market is led by the inexpensive and widely available laxatives. The clinical efficiency of laxatives is poor compared to its counterparts; however they still broadly used in constipation relief.
Europe was the largest market of the opioid-induced constipation market in 2015 in terms of value. It is then followed by North America. The market dominance of Europe is attributed the presence of a large number of baby boomers population in the region. North America was the fastest growing market for opioid-induced constipation in 2014, the market size of North America is expected to surpass the Europe during the forecast period. The high growth of the market is attributed to the supportive government incentive in healthcare services in addition with the presence of a large pool of patients suffering from chronic pain.
In September 2014 the U.S. Food and Drug Administration (FDA) has approved methyl naltrexone bromide hypodermic injection, 12 mg/0.6ml, for the treatment of opioid-induced constipation for the patients using opioids non-cancer chronic pain. This approval from the FDA is expected to serve approx. 11 million patients in the U.S. who are suffering from opioid-induced constipation.
Based on the different form of therapy the global opioid-induced constipation market can be broadly categorized as non-tamper resistant formulations (non-TRFs) and tamper resistant formulations (TRF). The non-TRFs has the largest market share in 2014, however the TRFs is expected to more dominant treatment technology in upcoming years attributed mainly to the U.S. Food and Drug Administration (FDA) promotions and broad pipeline of oral (TRFs) approval.
Request for Table of Content: https://www.psmarketresearch.com/enquiry-form.php?enqid=243&title=TOC
Some of the major players operating in the global opioid-induced constipation market include, AstraZeneca plc, Valeant Pharmaceuticals International Inc., Takeda Pharmaceutical Co. Ltd., Salix Pharmaceuticals, Ltd., Progenics Pharmaceuticals, Inc., Abbott Laborites, and Bayer AG among others.
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
P&S Market Research
Abhishek
18887787886
enquiry@psmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
